Literature DB >> 1838580

Heterogeneous dopamine receptor changes in early and late Huntington's disease.

E K Richfield1, C F O'Brien, T Eskin, I Shoulson.   

Abstract

Quantitative receptor autoradiography was used to study dopamine (DA) receptors in dorsal striatum and its projection regions in brains from individuals dying with Huntington's disease (HD) and controls. Heterogeneous loss of both D1 and D2 receptors was present in the striatum of early and late stage HD brains. The degree of receptor loss was greater for the D1 receptor than for the D2 receptor in early stage HD. The pattern of receptor loss did not correspond to heterogeneities identified with acetylcholinesterase staining. Progressive loss of D1 receptors in the internal globus pallidus and substantia nigra pars reticulata and D2 receptors in the external globus pallidus corresponded to advancing pathologic grade.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1838580     DOI: 10.1016/0304-3940(91)90448-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  34 in total

1.  Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice.

Authors:  A S Harris; E M Denovan-Wright; L C Hamilton; H A Robertson
Journal:  J Psychiatry Neurosci       Date:  2001-03       Impact factor: 6.186

2.  From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease.

Authors:  S W Davies; M Turmaine; B A Cozens; A S Raza; A Mahal; L Mangiarini; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 3.  Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.

Authors:  J H Cha; A S Frey; S A Alsdorf; J A Kerner; C M Kosinski; L Mangiarini; J B Penney; S W Davies; G P Bates; A B Young
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 4.  Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease.

Authors:  L Besret; A L Kendall; S B Dunnett
Journal:  J Anat       Date:  2000-05       Impact factor: 2.610

Review 5.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 6.  The application of NMR-based metabonomics in neurological disorders.

Authors:  Elaine Holmes; Tsz M Tsang; Sarah J Tabrizi
Journal:  NeuroRx       Date:  2006-07

7.  Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease.

Authors:  Dan P Covey; Hannah M Dantrassy; Samantha E Yohn; Alberto Castro; P Jeffrey Conn; Yolanda Mateo; Joseph F Cheer
Journal:  Neuropsychopharmacology       Date:  2018-06-01       Impact factor: 7.853

8.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

9.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

10.  Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

Authors:  G Sedvall; P Karlsson; A Lundin; M Anvret; T Suhara; C Halldin; L Farde
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.